Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00453102 · ClinicalTrials.gov registry record · Phase 2
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma
A Phase 2 study, sponsored by University of Miami.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00453102 is a Phase 2 study that has completed, run by University of Miami. The registered enrollment target is 18 participants.
The verdict
NCT00453102, a Phase 2 study, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).
Interventions
- DRUG Rituximab
- DRUG Ibritumomab Tiuxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-02 |
| Est. Completion | 2015-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00453102
The ClinicalTrials.gov registry entry for NCT00453102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00453102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00453102 about?
NCT00453102 is a clinical study titled "Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma". Zevalin may be an effective therapy for newly diagnosed marginal zone lymphoma (MZL).
What is the current status of trial NCT00453102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-02. Estimated completion is 2015-02.
What interventions are being tested in trial NCT00453102?
The interventions under investigation include: Rituximab (DRUG), Ibritumomab Tiuxetan (DRUG).
Who is sponsoring clinical trial NCT00453102?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.